Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.24 USD | -1.44% | +5.94% | -10.32% |
04-18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
04-17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.32% | 4.84B | |
+20.17% | 46.81B | |
-1.05% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.69% | 26.06B | |
-19.76% | 19.13B | |
+32.35% | 12.39B | |
+0.30% | 12.08B | |
-0.60% | 11.96B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : SVB Leerink Starts CRISPR Therapeutics at Outperform With $126 Price Target